Kiromic Biopharma, INC
Market Movers (8-K)
Kiromic BioPharma, Inc. has filed for Chapter 7 bankruptcy, leading to the resignation of its board of directors and termination of key officers.
Worse than expected
Kiromic BioPharma announces a significant cost-reduction measure by placing 31 employees on furlough, effective March 12, 2025, due to financial constraints.
Delay expected
Worse than expected
Capital raise
Kiromic BioPharma issued a $1 million senior secured convertible promissory note to an accredited investor, with a 25% interest rate and potential conversion into common stock.
Capital raise
Kiromic BioPharma has entered into a material definitive agreement, issuing a $1 million senior secured convertible promissory note to an accredited investor to support its CAR-T cell therapy development and for general corporate purposes.
Capital raise
Kiromic BioPharma has entered into a $2 million financing agreement by issuing a senior secured convertible promissory note to an accredited investor.
Worse than expected
Capital raise
Kiromic BioPharma has entered into an agreement to exchange $2.4 million in promissory notes plus accrued interest for preferred stock, reducing its debt by $3 million.
Quarterly Earnings (10-Q)
Kiromic Biopharma's Q3 2024 report reveals ongoing losses and a going concern warning, despite clinical trial progress with Deltacel.
Worse than expected
Capital raise
Kiromic Biopharma's Q2 2024 results reveal ongoing losses and a precarious financial position, raising substantial doubt about the company's ability to continue as a going concern.
Worse than expected
Capital raise
Kiromic BioPharma's Q1 2024 results show a net loss of $6.1 million and raise substantial doubt about the company's ability to continue as a going concern due to insufficient cash.
Delay expected
Worse than expected
Capital raise
Annual Reports (10-K)
Kiromic BioPharma's 2024 10-K filing highlights ongoing losses, a need for additional funding, and substantial doubt about the company's ability to continue as a going concern.
Worse than expected
Capital raise
Kiromic BioPharma has filed an amendment to its annual report to include previously omitted information and director signatures.
Capital raise
Kiromic BioPharma's 2023 annual report highlights progress in its Deltacel clinical trial and ongoing financial challenges.
Worse than expected
Capital raise
Insider Trading (Form 4)
Kiromic Biopharma's CEO, Pietro Bersani, recently purchased additional shares of the company's common stock, increasing his holdings.
Brian Hungerford, CFO of Kiromic Biopharma, recently acquired additional shares of the company's common stock through open market purchases.
Brian Hungerford, CFO of Kiromic Biopharma, recently purchased 2,000 shares of the company's common stock at a price of $1.75 per share.
Director Pamela Misajon recently purchased additional shares of Kiromic Biopharma, Inc., signaling a potential vote of confidence in the company.
Kiromic Biopharma's CFO, Brian Hungerford, purchased 1,000 shares of common stock at $2.60 per share on June 13, 2024.
Director Michael Nagel of Kiromic Biopharma, Inc. purchased 1,000 shares of common stock on June 11, 2024.
Proxy Statements (Def-14A)
Kiromic BioPharma is holding its annual meeting on June 26, 2024, seeking stockholder approval for director elections, auditor ratification, a share cap proposal, and a reverse stock split.
Capital raise
New Public Companies (S-1)
Kiromic Biopharma is seeking to raise capital through a unit offering to fund clinical development and working capital, contingent on listing its stock and warrants on the NYSE American.
Capital raise
Kiromic BioPharma is seeking to raise capital through a public offering of units, each consisting of one share of common stock and a warrant, to further its development of allogeneic Gamma Delta T-cell therapies for solid tumors.
Capital raise
Worse than expected